Myopia Control Therapeutic Lenses

About Clerio Vision

Clerio Vision is a private, pre-revenue medical device innovator leveraging its proprietary LIRIC (Laser Induced Refractive Index Change) platform to address multiple multi-billion-dollar ophthalmic markets. The technology, born from University of Rochester research, uses femtosecond lasers to 'write' corrective optics inside materials, enabling novel, non-invasive solutions for presbyopia, myopia progression, post-cataract optimization, and refractive surgery. With $80M in R&D investment, a strong IP portfolio, and completed first-in-human trials, Clerio is positioned to disrupt traditional vision correction paradigms if it can successfully navigate clinical development, regulatory pathways, and market adoption.

Therapeutic Areas

Other Myopia Progression Drugs